Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Importance: Cerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials. Objective: To investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia. Design, Setting, and Participants: This cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study. Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests. Mild cognitive impairment was diagnosed according to published criteria. Study inclusion began in 2013 and is ongoing. Data analysis was performed in January 2017. Main Outcomes and Measures: Global cognitive performance as assessed by the Mini-Mental State Examination (MMSE) and episodic memory performance as assessed by a verbal word learning test. Amyloid aggregation was measured with positron emission tomography or cerebrospinal fluid biomarkers and dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs. Generalized estimating equations were used to examine the association between amyloid aggregation and low cognitive scores (MMSE score ≤27 or memory z score≤-1.28) and to assess whether this association was moderated by age, sex, educational level, or apolipoprotein E genotype. Results: Among 2908 persons with normal cognition (mean [SD] age, 67.4 [12.8] years), amyloid positivity was associated with low memory scores after age 70 years (mean difference in amyloid positive vs negative, 4% [95% CI, 0%-7%] at 72 years and 21% [95% CI, 10%-33%] at 90 years) but was not associated with low MMSE scores (mean difference, 3% [95% CI, -1% to 6%], P = .16). Among 4133 patients with MCI (mean [SD] age, 70.2 [8.5] years), amyloid positivity was associated with low memory (mean difference, 16% [95% CI, 12%-20%], P < .001) and low MMSE (mean difference, 14% [95% CI, 12%-17%], P < .001) scores, and this association decreased with age. Low cognitive scores had limited utility for screening of amyloid positivity in persons with normal cognition and those with MCI. In persons with normal cognition, the age-related increase in low memory score paralleled the age-related increase in amyloid positivity with an intervening period of 10 to 15 years. Conclusions and Relevance: Although low memory scores are an early marker of amyloid positivity, their value as a screening measure for early AD among persons without dementia is limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Self-citationApolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
Self-citationPike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789
Self-citationPreclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564
Self-citationLongitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434
Self-citationJack, C. R., Wiste, H. J., Weigand, S. D., Rocca, W. A., Knopman, D. S., Mielke, M. M., Lowe, V. J., Senjem, M. L., Gunter, J. L., Preboske, G. M., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70194-2 · Cited by 358
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later
Roe, C. M., Fagan, A. M., Grant, E. A., Hassenstab, J., Moulder, K. L., Maue Dreyfus, D., Sutphen, C. L., Benzinger, T. L. S., Mintun, M. A., Holtzman, D. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182918ca6 · Cited by 222
Self-citationBurnham, S. C., Bourgeat, P., Doré, V., Savage, G., Brown, B., Laws, S., Maruff, P., Salvado, O., Ames, D., Martins, R. N., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30125-9 · Cited by 207
Self-citationPetersen, R. C., Wiste, H. J., Weigand, S. D., Rocca, W. A., Roberts, R. O., Mielke, M. M., Lowe, V. J., Knopman, D. S., Pankratz, V. S., Machulda, M. M., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3098 · Cited by 196
Aguirre-Acevedo, D. C., Lopera, F., Henao, E., Tirado, V., Muñoz, C., Giraldo, M., Bangdiwala, S. I., Reiman, E. M., Tariot, P. N., Langbaum, J. B., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4851 · Cited by 90
Disentangling the effects of age and APOE on neuropathology and late life cognitive decline
Yu, L., Boyle, P. A., Leurgans, S., Schneider, J. A., & Bennett, D. A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.074 · Cited by 71
Cited by
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Imaging the evolution and pathophysiology of Alzheimer disease
Jagust, W. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0067-3 · Cited by 604
Self-citationAssociations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease
Ossenkoppele, R., Smith, R., Ohlsson, T., Strandberg, O., Mattsson, N., Insel, P. S., Palmqvist, S., & Hansson, O. (2019) · Neurology · doi:10.1212/wnl.0000000000006875 · Cited by 317
Self-citationPrevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum
Jansen, W. J., Janssen, O., Tijms, B. M., Vos, S. J. B., Ossenkoppele, R., Visser, P. J., Amyloid Biomarker Study Group, Aarsland, D., Alcolea, D., Altomare, D., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.5216 · Cited by 290
Self-citationA walk through tau therapeutic strategies
Jadhav, S., Avila, J., Schöll, M., Kovacs, G. G., Kövari, E., Skrabana, R., Evans, L. D., Kontsekova, E., Malawska, B., de Silva, R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0664-z · Cited by 290
Metadata
- Authors
- Jansen, W. J., Ossenkoppele, R., Tijms, B. M., Fagan, A. M., Hansson, O., Klunk, W. E., van der Flier, W. M., Villemagne, V. L., Frisoni, G. B., Fleisher, A. S., Lleó, A., Mintun, M. A., Wallin, A., Engelborghs, S., Na, D. L., Chételat, G., Molinuevo, J. L., Landau, S. M., Mattsson, N., Kornhuber, J., Sabri, O., Rowe, C. C., Parnetti, L., Popp, J., Fladby, T., Jagust, W. J., Aalten, P., Lee, D. Y., Vandenberghe, R., Resende de Oliveira, C., Kapaki, E., Froelich, L., Ivanoiu, A., Gabryelewicz, T., Verbeek, M. M., Sanchez-Juan, P., Hildebrandt, H., Camus, V., Zboch, M., Brooks, D. J., Drzezga, A., Rinne, J. O., Newberg, A., de Mendonça, A., Sarazin, M., Rabinovici, G. D., Madsen, K., Kramberger, M. G., Nordberg, A., Mok, V., Mroczko, B., Wolk, D. A., Meyer, P. T., Tsolaki, M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Amyloid Biomarker Study Group, Aarsland, D., Alcolea, D., Alexander, M., Almdahl, I. S., Arnold, S. E., Baldeiras, I., Barthel, H., van Berckel, B. N. M., Blennow, K., van Buchem, M. A., Cavedo, E., Chen, K., Chipi, E., Cohen, A. D., Förster, S., Fortea, J., Frederiksen, K. S., Freund-Levi, Y., Gkatzima, O., Gordon, M. F., Grimmer, T., Hampel, H., Hausner, L., Hellwig, S., Herukka, S.-K., Johannsen, P., Klimkowicz-Mrowiec, A., Köhler, S., Koglin, N., van Laere, K., de Leon, M., Lisetti, V., Maier, W., Marcusson, J., Meulenbroek, O., Møllergård, H. M., Morris, J. C., Nordlund, A., Novak, G. P., Paraskevas, G. P., Perera, G., Peters, O., Ramakers, I. H. G. B., Rami, L., Rodríguez-Rodríguez, E., Roe, C. M., Rot, U., Rüther, E., Santana, I., Schröder, J., Seo, S. W., Soininen, H., Spiru, L., Stomrud, E., Struyfs, H., Teunissen, C. E., Vos, S. J. B., van Waalwijk van Doorn, L. J. C., Waldemar, G., Wallin, Å. K., Wiltfang, J., & Zetterberg, H.
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2018-01-01
- Volume
- 75
- Issue
- 1
- Pages
- 84
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2768948569
- Cited by
- 140
- References
- 13
- FWCI
- 14.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.